"Glutaminase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Descriptor ID |
D005972
|
MeSH Number(s) |
D08.811.277.087.483
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glutaminase".
Below are MeSH descriptors whose meaning is more specific than "Glutaminase".
This graph shows the total number of publications written about "Glutaminase" by people in this website by year, and whether "Glutaminase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2012 | 0 | 1 | 1 |
2014 | 2 | 1 | 3 |
2016 | 2 | 0 | 2 |
2017 | 0 | 1 | 1 |
2019 | 2 | 2 | 4 |
2020 | 3 | 0 | 3 |
2021 | 1 | 0 | 1 |
2022 | 0 | 3 | 3 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glutaminase" by people in Profiles.
-
Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma. Haematologica. 2023 06 01; 108(6):1616-1627.
-
In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma. Sci Adv. 2022 12 16; 8(50):eabp8293.
-
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA Oncol. 2022 10 01; 8(10):1411-1418.
-
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial. Clin Cancer Res. 2022 08 02; 28(15):3248-3255.
-
A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer. Proc Natl Acad Sci U S A. 2021 03 30; 118(13).
-
Circ_0000003 regulates glutamine metabolism and tumor progression of tongue squamous cell carcinoma via the miR-330-3p/GLS axis. Oncol Rep. 2021 04; 45(4).
-
The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies. Mol Cancer Ther. 2021 03; 20(3):500-511.
-
STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition. Clin Cancer Res. 2021 03 15; 27(6):1720-1733.
-
Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. J Med Chem. 2020 11 12; 63(21):12957-12977.
-
Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer. Cell Rep. 2019 10 01; 29(1):76-88.e7.